Edwards Lifesciences Corp  

(Public, NYSE:EW)   Watch this stock  
Find more results for EDWARDS
+1.60 (1.42%)
Real-time:   12:10PM EDT
NYSE real-time data - Disclaimer
Currency in USD
Range 112.70 - 114.69
52 week 62.53 - 117.46
Open 113.00
Vol / Avg. 412,447.00/1.69M
Mkt cap 23.96B
P/E 47.40
Div/yield     -
EPS 2.42
Shares 211.90M
Beta 0.57
Inst. own 88%
Oct 24, 2016
Q3 2016 Edwards Lifesciences Corp Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jul 26, 2016
Q2 2016 Edwards Lifesciences Corp Earnings Call
Jul 26, 2016
Q2 2016 Edwards Lifesciences Corp Earnings Release
Jun 7, 2016
Edwards Lifesciences Corp at Goldman Sachs Global Healthcare Conference
May 13, 2016
Edwards Lifesciences Corp Annual Shareholders Meeting (Estimated)
May 12, 2016
Edwards Lifesciences Corp Annual Shareholders Meeting
May 4, 2016
Edwards Lifesciences Corp at Deutsche Bank Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin 16.67% 19.85%
Operating margin 22.26% 24.96%
EBITD margin - 28.44%
Return on average assets 12.85% 13.05%
Return on average equity 21.29% 21.08%
Employees 9,800 -
CDP Score - 82 D


1 Edwards Way
IRVINE, CA 92614-5688
United States - Map
+1-949-2502500 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company manufactures heart valve systems and repair products used to replace or repair a patient's diseased or defective heart valve. It develops hemodynamic monitoring systems used to measure a patient's cardiovascular function in the hospital setting. The Company conducts operations around the world and is managed in various geographical regions, including the United States, Europe, Japan, and Rest of World. All regions sell products that are used to treat advanced cardiovascular disease. The Company's products and technologies it offers to treat advanced cardiovascular disease are categorized into three areas: Transcatheter Heart Valve Therapy, Surgical Heart Valve Therapy and Critical Care.

Officers and directors

Michael A. Mussallem Chairman of the Board, Chief Executive Officer
Age: 63
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Scott B. Ullem Chief Financial Officer, Corporate Vice President
Age: 49
Bio & Compensation  - Reuters
Donald E. Bobo Jr. Corporate Vice President - Heart Valve Therapy
Age: 54
Bio & Compensation  - Reuters
Catherine M. Szyman Corporate Vice President, Critical Care
Age: 49
Bio & Compensation  - Reuters
Patrick Bruno Verguet Corporate Vice President, Europe, Middle East and Africa
Age: 58
Bio & Compensation  - Reuters
Huimin Wang M.D. Corporate Vice President, Japan, Asia Pacific
Age: 59
Bio & Compensation  - Reuters
Larry L. Wood Corporate Vice President - Transcatheter Heart Valve Therapy
Age: 50
Bio & Compensation  - Reuters
Leslie Stone Heisz Director
Age: 55
Bio & Compensation  - Reuters
Steven R. Loranger Director
Age: 64
Bio & Compensation  - Reuters
Martha H. Marsh Director
Age: 67
Bio & Compensation  - Reuters